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ABSTRACT
Zebrafish larvae are increasingly used for pharmacological
research, but internal drug exposure is often not measured.
Understanding pharmacokinetics is necessary for reliable
translation of pharmacological results to higher vertebrates,
including humans. Quantification of drug clearance and distri-
bution requires measurements of blood concentrations. Addi-
tionally, measuring drug metabolites is of importance to
understand clearance in this model organism mechanistically.
We therefore mechanistically studied and quantified pharma-
cokinetics in zebrafish larvae, and compared this to higher
vertebrates, using paracetamol (acetaminophen) as a paradigm
compound. A method was developed to sample blood from
zebrafish larvae 5 days post fertilization. Blood concentrations
of paracetamol and its major metabolites, paracetamol-
glucuronide and paracetamol-sulfate, were measured. Blood
concentration data were combined with measured amounts in
larval homogenates and excreted amounts and simultaneously
analyzed through nonlinear mixed-effects modeling, quantify-
ing absolute clearance and distribution volume. Blood sam-
pling from zebrafish larvae was most successful from the
posterior cardinal vein, with a median volume (interquartile
range) of 1.12 nl (0.676–1.66 nl) per blood sample. Samples
were pooled (n 5 15–35) to reach measurable levels.
Paracetamol blood concentrations at steady state were only
10% of the external paracetamol concentration. Paracetamol-
sulfate was the major metabolite, and its formation was
quantified using a time-dependent metabolic formation rate.
Absolute clearance and distribution volume correlated well with
reported values in higher vertebrates, including humans. Based
on blood concentrations and advanced data analysis, the
mechanistic and quantitative understanding of paracetamol
pharmacokinetics in zebrafish larvae has been established.
This will improve the translational value of this vertebrate model
organism in drug discovery and development.
SIGNIFICANCE STATEMENT
In early phases of drug development, new compounds are
increasingly screened in zebrafish larvae, but the internal drug
exposure is often not taken into consideration. We developed
innovative experimental and computational methods, including
a blood-sampling technique, to measure the paradigm drug
paracetamol (acetaminophen) and its major metabolites and
quantify pharmacokinetics (absorption, distribution, elimination)
in zebrafish larvae of 5 days post fertilization with a total volume
of only 300 nl. These parameter values were scaled to higher
vertebrates, including humans.
Introduction
In drug discovery and development, the zebrafish (Danio
rerio) larva is a promising vertebratemodel organism (Zon and
Peterson, 2005; MacRae and Peterson, 2015). It has many
advantages, including 70% genetic homology to humans
(Howe et al., 2013), the possibility of high-throughput
experimentation, easy genetic modification, and imaging
of internal processes due to its transparency in early life
((Van Wijk et al., 2016; Schulthess et al., 2018)). In experi-
ments with zebrafish larvae, it is common practice to expose
the larvae to study drugs by waterborne treatment, dissolv-
ing the drug of interest in the medium in which the larvae
swim. Ignoring the internal exposure, as is done in this
approach, potentially leads to false positives or negatives
(Diekmann and Hill, 2013). More importantly, translation
of pharmacological findings to higher vertebrates is very
limited without an internal exposure-response relationship
((Morgan et al., 2012; Van Wijk et al., 2016)). To be able to
use zebrafish larvae to their full potential in pharmacological
research, a mechanistic understanding of the pharmacokinetic
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processes in zebrafish larvae is needed together with a frame-
work to quantitatively scale this to higher vertebrates.
Methods to measure internal drug amounts in larval
homogenates over time have been established only recently
(Kühnert et al., 2013, 2017; Vogs et al., 2015; Kantae et al.,
2016). In the case of our paradigm compound paracetamol
(acetaminophen), internal paracetamol amounts were sub-
sequently used to quantify the pharmacokinetic processes of
absorption and elimination through quantification of the rate
of absorption and a clearance relative to total larval volume.
Although the clearance derived from relative values in zebra-
fish larvae scaled quite reasonably to reported absolute
clearance values in higher vertebrates ((Kantae et al., 2016;
Van Wijk et al., 2019)), accurate scaling of clearance requires
absolute clearance values in zebrafish larvae. However,
quantification of absolute clearance requires blood concen-
trations, which will also allow for the estimation of a distribu-
tion volume, but blood-sampling methods for zebrafish larvae
that are only a few hundred nanoliters in total volume (Guo
et al., 2017) have not yet been described.
In addition, mechanistic characterization of metabolic
clearance in zebrafish larvae is of importance, as the utility
of zebrafish larvae in drug development depends on their
drug metabolism being similar to higher vertebrates in
a qualitative (similar metabolites) and quantitative (similar
rate and extent) manner. This is because drugmetabolites can
be pharmacologically active or toxic. A first step in assessing
mechanistic similarities in drug metabolism between verte-
brate species is genetic confirmation, through DNA sequenc-
ing and gene expression of the enzymes and possible cofactors,
that similar enzymatic pathways are present in the zebrafish.
For example, our paradigm compound paracetamol is a sub-
strate for two important metabolic pathways, glucuronidation
and sulfation (Janus et al., 2003; Neirinckx et al., 2010; Lee
et al., 2012; Owens et al., 2012). In zebrafish, the enzyme
systems for these pathways have been documented based on
genetic homology with humans ((Van den Boom et al., 2012;
Van Wijk et al., 2016)). However, functional and quantitative
confirmation that drugmetabolites are actually formed in vivo
and at what rate they are formed and eliminated is crucial.
This is currently lacking for most enzymatic pathways that
metabolize drugs in zebrafish larvae.
Here, the objective is to mechanistically and quantitatively
study pharmacokinetics in zebrafish larvae. To that aim,
a method is developed to take nanoscale blood samples to
measure paracetamol and its major metabolites. A mechanis-
tic metabolite model is developed to quantify paracetamol
absolute clearance and distribution volume, which are com-
pared with those from higher vertebrates, including humans.
Materials and Methods
Experimental Design. Experiments were performed in zebrafish
(D. rerio) larvae of 5 days post fertilization (dpf), as this age is within
the ethically acceptable time frame for larval experiments, and it
offers the largest capacity to metabolize paracetamol within that time
frame (Van Wijk et al., 2019). The investigation was divided into two
experiments. In the first experiment, larvae were continuously
treated with 1 mM waterborne paracetamol concentration in embryo
medium for up to 200 minutes. In the second experiment, larvae were
treated with 1 mM waterborne paracetamol concentration for
60 minutes, then washed and transferred to clean washout embryo
medium, and elimination was studied over 240 minutes.
A newmethodwas developed to sample blood from zebrafish larvae.
Blood samples were taken during the first experiment. Observations
between 10 and 125 minutes of waterborne treatment consisted of
minimal three replicates of 15–35 pooled blood samples. These data
were combined with data from a previous study, which included six
replicates of measured paracetamol amounts in whole larval homo-
genates of five zebrafish larvae at 10–180 minutes in the first
experiment and 60–300 minutes in the second experiment (Van Wijk
et al., 2019). Additionally, six replicates of washout medium of the
second experiment were sampled at 60–300 minutes to measure
excreted paracetamol and metabolites.
Paracetamol and its two major metabolites, paracetamol-
glucuronide and paracetamol-sulfate, were measured in blood, me-
dium, and homogenate samples by liquid chromatography–mass
spectrometry (LC-MS). Nonlinear mixed-effects modeling was per-
formed on all data simultaneously to quantify absolute clearance,
including metabolic formation and elimination rates and distribution
volume. Finally, obtained parameter values for absolute clearance and
distribution volume were compared with published values in higher
vertebrates.
Zebrafish Larvae Husbandry. Maintenance and handling of
zebrafish followed international consensus protocols (Westerfield,
2000), and the planning and execution of all experiments were
compliant with European regulation (European Union, 2010). Adult
wild-type AB/TL zebrafish were used to fertilize eggs and kept in glass
aquaria (max 6/l, volume 10 l, 120 220 490mm; Fleuren&Nooijen
BV, Nederweert, The Netherlands) with circulating water at 27.7 6
0.1C on a 14-hour/10-hour light/dark cycle (lights on at 08:00) and
twice daily feeding with artemia or feed particles (Gemma Micro/
Diamond, Skretting; Nutreco NV, Amersfoort, The Netherlands).
Water quality was controlled by JUMO Acquis touch S (JUMOGmbH
&Co., Weesp, The Netherlands). Fertilized eggs were collected within
20 minutes of fertilization. Eggs and larvae were kept at 28C in
embryo medium, which was refreshed daily. Exposure experiments
were performed at room temperature.
Blood Sampling. To develop a method for blood sampling from
zebrafish larvae at 5 dpf, larvae were washed with embryo medium
using Netwell insert filters (Corning Life Sciences B.V., Amsterdam,
The Netherlands) and transferred to a microscope slide coated with
agarose. Larvae were not anesthetized to prevent decreased blood
flow; instead, superficial drying with soft lens paper prevented
movement.
Sampling was performed using a needle pulled by a micropipette
puller (Sutter Instruments, Novato, CA) from a 0.75-mm borosilicate
glass capillary (Sutter Instruments) without filament, positioned in
a micromanipulator (World Precision Instruments, Berlin, Germany),
connected to a manual CellTram Vario oil pump (Eppendorf Neder-
land B.V., Nijmegen, The Netherlands), under 20 magnification
(Leica, Amsterdam, The Netherlands). After decapitation or tail cut
was found to result in limited yields, direct sampling from the
circulation was explored. To identify the most suitable location,
sampling from different anatomic locations was tested (Isogai et al.,
2001), including the heart, the dorsal aorta, the caudal vein, and the
posterior cardinal vein.
An image was taken from each blood sample in the needle to
determine the sample volume. The image analysis program Fiji
(Schindelin et al., 2012) was used to calculate the volume of the blood















where r1 and r2 are the upper and lower radii of the blood sample in the
pulled needle, and h is the length of the blood samplewithin the needle
taking into account the 45 angle of the needle with respect to the
microscope. After the blood sample was imaged, it was injected into
a 2-ml droplet of heparin solution (5 International Units/ml) under











microscope both to prevent coagulation and for sample handling.
Sample replicates consisted of blood samples from 15–35 larvae to
reach measurable levels, of which the total number depended on
experimental and time constraints, and were pooled into a 0.5-ml
Eppendorf tube and stored at 280C.
Measurements of Paracetamol and Its Metabolites. On the
day of measurement, blood samples were thawed and 200 ml of
methanol with paracetamol-D4 internal standard (1.4 pg/ml) was
added. Samples were centrifuged (16,000g, 10 minutes) and 180 ml of
supernatant was transferred to a 0.5-ml Eppendorf tube to be
evaporated by vacuum centrifuge (Beun-de Ronde, Abcoude, The
Netherlands) until dry. Samples were reconstituted in 10 ml of 80/20
(v/v) purified water/methanol and transferred to an LC-MS vial for
randomized injection of 7 ml into the ultraperformance liquid chro-
matography system (Acquity; Waters Chromatography B.V., Etten-
Leur, The Netherlands) linked to a quadrupole ion trap MS/MS
(QTRAP-6500; AB Sciex B.V., Nieuwekerk aan den IJssel, The
Netherlands). An electrospray ionization source in positive (para-
cetamol) and negative (paracetamol-glucuronide and paracetamol-
sulfate) mode was used as published before ((Kantae et al., 2016; Van
Wijk et al., 2019)). Method criteria were 90%–100% accuracy and
a precision corresponding to a relative S.D. less than 10%. Lower limit
of quantification (LLOQ) in blood samples was 0.05 pg/ml for para-
cetamol and paracetamol-sulfate and 5 pg/ml for paracetamol-
glucuronide.
The homogenate samples were measured as described before
((Kantae et al., 2016; Van Wijk et al., 2019)). LLOQ in homogenates
was 0.09 pg/ml for paracetamol and paracetamol-sulfate and 9.0 pg/ml
for paracetamol-glucuronide. Of the washout medium of the second
experiment, samples of 1850 ml were collected and stored at 280C.
On the day of measurement, samples were thawed, 10 ml of 125-pg/ml
paracetamol-D4 internal standard was added, and samples were
evaporated by vacuum centrifuge until dry. Samples were reconsti-
tuted in 50 ml of purified water and centrifuged (16,000g, 15 minutes),
and 25 ml of supernatant was transferred to an LC-MS vial for
randomized injection of 5 ml into the LC-MS system as described
earlier. Background measurement of the washout medium at t 5 60
was subtracted from the sample measurements. A calibration curve
ranging from 0.05 to 100 pg/ml was prepared in 50/50 (v/v) methanol/
purified water and was used to calculate compound-excreted amounts
in picomoles per larva. LLOQ in washout medium was 0.05 pg/ml for
paracetamol and paracetamol-sulfate and 5 pg/ml for paracetamol-
glucuronide.
Pharmacokinetic Data Analysis. Apharmacokinetic model was
developed for paracetamol and its metabolites using nonlinear mixed-
effects modeling. NONMEM (version 7.3) (Beal et al.) was used
through interfaces Pirana (version 2.9.6) (Keizer et al., 2011) and
PsN (version 4.7.0) (Lindbom et al., 2005), and graphical output was
created using R (version 3.4.2) (R Core Team., 2014) through the
RStudio interface (version 1.1.383; RStudio Inc., Boston, MA).
The first-order conditional estimation algorithm was used. A zero-
order absorption rate constant was estimated to quantify paracetamol
absorption from the surrounding medium, as we have previously
shown that paracetamol concentrations in the treatment medium
remain constant during the experiments (Van Wijk et al., 2019). One-
and two-compartment models were tested for the distribution of each
compound. Linear and nonlinear metabolic clearance for paracetamol
was tested, including one- and two-substrate Michaelis-Menten
kinetics (Ingalls, 2012), the latter of which was used to account for
possible saturation of the sulfation pathway caused by depletion of the
sulfate group donor 39-phosphoadenosine 59-phosphosulfate (PAPS)
(Reddyhoff et al., 2015). Last, time-dependent metabolism using both
exponential and sigmoidal relationships was tested (Brochot et al.,
2011). First-order rates of excretion into medium with or without
recovery fractions were estimated per compound.
Because of the destructive sampling, interindividual variabil-
ity could not be distinguished from residual variability; therefore,
only the latter was estimated, using an additive, proportional, or
a combination of additive and proportional error per compound per
sample type. Level 2 covariance between the residual error for
compounds measured in the same sample was tested (Karlsson
et al., 1995). All compounds had less than 10% of data points below
the limit of quantification, with the sole exception of paracetamol-
glucuronide in blood samples (71%), warranting the M2 method of
ignoring these values in the analysis (Beal, 2001).
Model selection was based on the likelihood ratio test between
nested models, using a drop in objective function value of 6.63
between nestedmodels to indicate statistical significance, correspond-
ing to P , 0.01 assuming a x2 distribution. Additionally, physiologic
plausibility of parameter estimates and goodness-of-fit plots were
assessed (Nguyen et al., 2017). Structural parameter precision was
considered acceptable when relative standard errors (RSE) were
below 50%.
Comparison of Absolute Clearance and Distribution Vol-
ume of Paracetamol to Higher Vertebrates. The estimate of
absolute paracetamol clearance was comparedwith values reported in
higher vertebrates as previously published (Kantae et al., 2016), as
was the estimate of the distribution volume. For the latter, similar to
the comparison of clearance values, a literature search was performed
in PubMed using “distribution volumeOR volume of distribution AND
paracetamol OR acetaminophen.” Only values published in the last
20 years were included. Values obtained from specific disease models,
from combination treatment, or from obese patients, and from models
with more than one compartment for paracetamol distribution were
excluded. A regression through the log-transformed parameter values
based on log-transformed bodyweight was calculated including
95% confidence interval usingR (v.3.4.2) (RCoreTeam., 2014) through
user interface RStudio (v.1.1.383; RStudio Inc.). This regression was
based on data from mature individuals only, comparable to that of
paracetamol clearance. The bodyweight of the larvae was calculated
from their previously published volume (Guo et al., 2017) and an
assumed density of 0.997 g/ml, corresponding to that of water (Kantae
et al., 2016).
Materials. Paracetamol, paracetamol-glucuronide, paracetamol-
sulfate, and paracetamol-D4 internal standard were acquired from
Sigma-Aldrich Chemie B.V. (Zwijndrecht, The Netherlands). Heparin
was acquired from Academic Hospital Pharmacy Leiden (Leiden
UniversityMedical Center, Leiden, TheNetherlands). Embryomedium
consisted of demineralizedwater containing60mg/ml InstantOcean sea
salts (Sera, Heinsberg, Germany). Agarose was acquired from Sphaero
(Gorinchem, The Netherlands). Ultraperformance liquid chromatogra-
phy/mass spectrometry–grade MeOH was acquired from Biosolve B.V.
(Valkenswaard, The Netherlands). PURELAB (Veolia Water Technol-
ogies B.V., Ede, The Netherlands) was used to purify water.
Results
Blood Sampling. From the different anatomic locations,
the posterior cardinal vein proved most efficient for blood
sampling and resulted in a median volume of 1.12 nl per larva
with an interquartile range of 0.676–1.66 nl. Figure 1 and
Supplementary Video showthis procedure. The sample vol-
ume was determined based on a separately captured image of
the blood sample within the needle. Supplemental Table 1
lists the number blood samples that were pooled for each
sampling time point.
Measurement of Paracetamol and Metabolites. Para-
cetamol, paracetamol-glucuronide, and paracetamol-sulfate
could be measured in the blood samples, of which representa-
tive chromatograms are shown in Supplemental Fig. 1. The
symbols in Fig. 2 show paracetamol and metabolite concen-
trations and total amounts in blood samples and in homoge-
nates and washout medium, respectively. Although the data
are variable, clear trends can be observed.











The paracetamol and metabolite concentrations (Fig. 2, top
panel) could be measured in the nanoscale blood samples and
show that the sulfate metabolite reaches similar concentra-
tions as the parent, while concentrations of the glucuronide
metabolite are about 10-fold lower. This is similar to the
observations in homogenates (Fig. 2, middle panel). Para-
cetamol concentrations reach a steady-state value around
0.1 mM or 15 mg/l, which is 10% of the paracetamol
concentration in the treatment medium.
The paracetamol amounts in larval homogenate from the
washout experiment (Fig. 2, open symbols) show a monoexpo-
nential decline of paracetamol. For the metabolites, the washout
experiment shows an increase in internal amounts between 60
and120minutes, afterwhichparacetamol-glucuronide decreases
to 1 pmol/larva and paracetamol-sulfate stabilizes between 10
and 20 pmol/larva at 300 minutes.
The amounts of paracetamol, paracetamol-glucuronide, and
paracetamol-sulfate excreted into the medium during the
washout experiment are shown in Fig. 2 (bottom panel). These
data show low values with high variability and a minor
increase over the washout period.
Pharmacokinetic Data Analysis. Figure 3 shows a sche-
matic representation of the developed parent-metabolite
model for paracetamol. A model with zero-order absorption
and one compartment per compound best fit the data. The
formation of paracetamol-glucuronide was best describedwith
a first-order metabolic formation rate, whereas the para-
cetamol sulfation rate could not be captured with a zero- or
first-order metabolic formation rate, as both methods led to
underpredictions at earlier time points and overprediction at
later time points. Conventional Michaelis-Menten kinetics
depending on parent compound concentrations could not be
identified for paracetamol-sulfate, nor could a two-substrate
Michaelis-Menten kinetic model, which represents the poten-
tial rate-limiting influence of depletion of the sulfate group
donor as well. Regarding functions based on time-related
changes in sulfation rate, a sigmoidal function as described by
eq. 2 was statistically significantly better than an exponen-









where kPS,f is the metabolic formation rate for sulfation in
min21, kPS,f,0 is the metabolic formation rate for sulfation at
time point 0 in min21, t is the time in minutes, and t50 is the
time in minutes at which the formation rate for the sulfate
metabolite is at 50% of its value at time 0.
The excretion of paracetamol and its metabolites was best
captured with a first-order rate constant. A recovery fraction
on the excreted paracetamol and metabolite amounts was
included to prevent overestimation of the excreted com-
pounds, which resulted in a significantly improved fit both
graphically and statistically. Figure 4 shows the paracetamol
clearance over time as a sum of the constant metabolic
formation rate for glucuronidation, the excretion rate, and
the time-dependent metabolic formation rate for sulfation
according to the model.
Residual variability for homogenate samples was found
to be best described with a combination of additive and
proportional error for paracetamol and paracetamol-
glucuronide and with a proportional error for paracetamol-
sulfate, including covariance between the proportional errors
of paracetamol and paracetamol-glucuronide and between
the proportional errors of paracetamol-glucuronide and
paracetamol-sulfate. Residual variability for blood samples
was best described with an additive error for paracetamol
and proportional errors for paracetamol-glucuronide and
for paracetamol-sulfate. The residual variability for me-
dium samples was best described by an additive error for
paracetamol, a proportional error for paracetamol-glucuronide,
and a combination of additive and proportional for
paracetamol-sulfate.
Themodel predictions (lines) relative to the observed values
(symbols) are shown in Fig. 2 and show a good description of
the data. Table 1 contains the parameter estimates including
RSE as a measure of their precision of the final model. RSEs
for structural parameters were acceptable. Additional good-
ness-of-fit-plots, showing goodmodel accuracy, can be found in
Supplemental Figs. 2–4.
The final model code and data set are available through the
Drug Disease Model Resources (DDMoRe) Repository, Model
ID DDMODEL00000300 (http://repository.ddmore.foundation/
model/DDMODEL00000300).
Comparison of Absolute Clearance and Distribution
Volume of Paracetamol to Higher Vertebrates. A corre-
lation between paracetamol clearance and bodyweight in 12
higher vertebrates, including humans, has been reported
before (calculated exponent 5 0.78, 95% confidence interval:
0.65–0.91, R2 5 0.90) ((Kantae et al., 2016; Van Wijk et al.,
2019)). Paracetamol clearance estimated from homogenate
data alone, assuming homogeneous distribution of the drug
throughout the whole larvae, fell outside of the 95% confidence
interval of this correlation (Van Wijk et al., 2019). Here,
absolute paracetamol clearance is estimated by simulta-
neously modeling observed concentrations from blood
samples, which could be quantified as the result of the
blood-samplingmethod developed here, and observed internal
amounts from homogenates. Figure 5 shows the estimated
absolute paracetamol clearance of the zebrafish larva in
relation to that of 12 higher vertebrates. Because of the
time-dependent metabolic formation rate for sulfation, the
full range from paracetamol clearance at t5 0 (solid square) to
paracetamol clearance at t 5 ‘ (open square) is shown. This
range is partly within the 95% confidence interval. Noticeably,
clearance values from higher immature vertebrates are also
overpredicted by the correlation based on the values reported
for mature organisms.
Fig. 1. Blood sampling from posterior cardinal vein in a zebrafish larva at
5 days post fertilization using a pulled needle. Blood sample is shown in
needle tip.











The literature search resulted in reported values for the
distribution volume of paracetamol in 13 higher vertebrates,
which are provided with their references in Supplemental
Table 2. A correlation between the distribution volume of
paracetamol and bodyweight based on data obtained from
mature individuals of the higher vertebrates only is shown
in Fig. 6 (dashed line including 95% confidence interval).
The exponent in this relationship was calculated to be
0.94 (95% confidence interval: 0.67–1.2, R2 5 0.68). Although
5 orders of magnitude removed from the smallest higher
vertebrate, the distribution volume of paracetamol in zebra-
fish larvae lies well within the 95% confidence interval of the
correlation between distribution volume and bodyweight.
Even though the values from immature organisms are not
taken into account for the correlation between the distribution
volume of paracetamol and bodyweight, the data points are in
agreement with that correlation.
Discussion
Mechanistic and quantitative characterization of pharma-
cokinetics in zebrafish larvae is crucial for this vertebrate
model organism to deliver on its promising role in pharmaco-
logical research. To date, amethod to take blood samples, which
are essential to characterize pharmacokinetics, was lacking.
The quantification of absolute clearance and distribution
volume in zebrafish larvae, needed for reliable extrapolation
of pharmacokinetics between species, required measurements
Fig. 2. Paracetamol (blue circles, left column), paracetamol-glucuronide (magenta triangles, middle column), and paracetamol-sulfate (orange squares,
right column) observations in blood samples (top row, concentrations) as well as in homogenates (middle row, amounts) and excreted into medium
(bottom row, amounts) after constant waterborne treatment (solid symbols) and washout (open symbols) experiments. Blood concentrations are shown in
picomoles per nanoliters (millimolar). The model prediction is shown as a solid or dotted line for the constant waterborne treatment or washout
experiment, respectively. The lower number of data points of paracetamol-glucuronide is explained by its lower limit of quantification being higher than
that of the other compounds. Paracetamol observations in homogenates have been reported previously (Van Wijk et al., 2019).











of these blood concentrations in addition to knowing drug
amounts in larval homogenates as a determinant of the
bioavailable dose. This is analogous to the well known re-
quirement of knowing both blood concentrations and absolute
administered drug amounts by intravenous drug administra-
tion to quantify absolute pharmacokinetic parameters of
extravascular-administered drugs. Additionally, confirmation
of functional drug metabolism is of importance, because drug
metabolites can be pharmacologically active or toxic.
We report, for the first time, a method for nanoscale blood
sampling from zebrafish larvae at five dpf, in which not only
the paradigm compound paracetamol but also its two major
metabolites were measured. Absolute clearance of para-
cetamol in zebrafish larvae correlated reasonably well with
that reported in higher vertebrates. Results from our study
suggest that, in addition to the presence of genetic homology
for the enzymatic systems established before (VanWijk et al.,
2016), these metabolic pathways also behave functionally
similarly to higher vertebrates, as both metabolites are
present. Quantitatively, the ratio between the two metabo-
lites was different from those reported in mature humans
(Reith et al., 2009). Paracetamol-sulfate proved to be the
major metabolite at this larval stage with respect to
paracetamol-glucuronide. A similar profile, however, has
been shown in human newborns and infants, resulting from
limited glucuronidation capacity, which increases with in-
creasing age (Anderson et al., 2002; Krekels et al., 2015). This
is not unexpected, as zebrafish larvae have also not reached
maturity. Consequently, the impact of enzymatic maturation
needs to be taken into account when translating results from
immature zebrafish larvae to mature individuals of higher
vertebrates.
Metabolic formation rate for sulfation could not be accu-
rately captured using time-constant parameters. A conven-
tional Michaelis-Menten model could not accurately
describe the observed pharmacokinetic profiles. Therefore,
a two-substrate Michaelis-Menten kinetic model was tested,
accounting for the concentrations of both the substrate para-
cetamol and a hypothetical donor group, representing the
sulfate group donor PAPS, which may limit the biotransfor-
mation (Slattery et al., 1987; Liu and Klaassen, 1996; Red-
dyhoff et al., 2015). The data, however, did not allow for
reliable and stable estimation of the relevant model parame-
ters. Therefore, an empirical time-dependent function was
tested, with a sigmoidal time-dependent metabolic formation
rate resulting in the best fit but with relatively high RSE
values of the estimated parameters. Normalization of the
metabolic formation rate for sulfation at time point 0, kPS,f,0, at
a different time point reduced its RSE value below 50%,
indicating no overparameterization (Goulooze et al., 2019).
Supplemental Fig. 5 shows the paracetamol-sulfate fit of the
metabolite model, in which the time-dependent metabolic
formation rate for sulfation was replaced by a time-constant
first-order rate. The parameters of that model are estimated
with acceptable precision (RSE , 50%), but a clear misfit of
the paracetamol-sulfate data can be observed. The low t50
estimate resulted in a steep decline of sulfation in the first
minutes of the experiment (Fig. 4). We believe this function
represents the impact of depletion of the sulfate group donor
PAPS on the metabolic formation rate, as the shape of this
curve is similar to the shape of simulated PAPS levels from
a reported physiologic mathematical model at the cellular
level (Reddyhoff et al., 2015). As time approached infinity,
sulfation nears the asymptote of zero metabolic formation
rate. This is unlikely, as, for example, the sulfate group donor
PAPS is expected to be produced by the organism at a constant
rate, but this production rate could not be estimated with the
current data and time scale (Reddyhoff et al., 2015).
Fig. 3. Schematic representation of the structural pharmacokinetic
model of paracetamol and its metabolites in zebrafish larvae. Compart-
ments depicted with solid lines represent compartments in which both
amounts in homogenized larvae or blood concentrations in larvae were
available. Compartments indicated with dashed lines represent compart-
ments in which excreted amounts in the medium were available. ka,
absorption rate constant; kP,e, paracetamol excretion rate; kPS,f, metabolic
formation rate for sulfation; kPG,f, metabolic formation rate for glucur-
onidation; kG,e, paracetamol-glucuronide excretion rate; kS,e, paracetamol-
sulfate excretion rate; P, paracetamol; G, paracetamol-glucuronide; S,
paracetamol-sulfate.
Fig. 4. Paracetamol clearance over time. Total clear-
ance (transparent green solid line) is the sum of the
time-dependent metabolic formation rate for sulfation
(orange dashed line), the metabolic formation rate for
glucuronidation (magenta dotted line), and the un-
changed excretion rate (blue solid line).











Consequently, interpretation of this model is limited to the
time course presented here.
The availability of blood concentrations in addition to
absolute internal amounts allowed for the estimation of
absolute values for distribution volume for both the parent
and the major metabolites, which is unique. Figure 2 shows
variable data yielded from extremely small samples and low
concentrations; however, this did not limit accurate estima-
tion of distribution volumes, as indicated by RSE values being
25% or lower. The estimated distribution volume of para-
cetamol in zebrafish larvae correlatedwell with those reported
in higher vertebrates. The estimated distribution volumes for
the glucuronide and sulfate metabolites are 0.6 and 1.2 the
distribution volume of paracetamol, respectively. Reported
values show large variability and range 0.2–1.6 that of
paracetamol for paracetamol glucuronide and 0.09–0.9
that of paracetamol for paracetamol-sulfate in humans
((Lowenthal et al., 1976; Owens et al., 2012, 2014; Van Rongen
et al., 2016)), and 1.2–2.7 for paracetamol glucuronide and
0.25–1.5 for paracetamol-sulfate in rats (Yamasaki et al.,
2011; Lee et al., 2012). These values are in line with our
estimates, but care must be taken when interpreting these
data. Determining distribution volume of drug metabolites had
to be done in patients who all had specific conditions which also
impacted normal physiology. In the zebrafish, the total amounts
necessary were readily available for that determination.
The developed method of blood sampling results in blood
samples at the nanoliter scale. Multiple blood samples have to
be pooled into a single analytical replicate to quantify drug
and metabolite concentrations by conventional LC-MS. To
improve throughput and efficiency, nanoelectrospray ioniza-
tionmass spectrometry could be considered (Fujii et al., 2015).
This technique directly injects a sample of sub-nanoliter
volumes together with ionization solvent into an electron
spray ionization source and has, for instance, been used to
sample and quantify concentrations of the anticancer drug
tamoxifen in individual cancer cells (Ali et al., 2019).
Currently, the high-throughput potential in zebrafish larvae
for the purpose of obtaining absolute pharmacokinetic pa-
rameter values required for interspecies scaling is limited by
the practicalities of the blood sampling and by the need for
the development of highly sensitive analytical methods for
these samples. We, however, envision that this step is only
performed for promising drug candidates that have been
selected for further development. Additionally, microinjec-
tion of zebrafish zygotes and embryos has been automated,
resulting in higher throughput (Spaink et al., 2013; Cordero-
Maldonado et al., 2019). In the future, this technique might
also be applicable to sampling.
We have confirmed that the paracetamol metabolites are
formed by metabolizing enzymes of the zebrafish larvae and
not by metabolizing enzymes of the microbiota by repeating
TABLE 1
















VP (nl) 218 24
VG (nl) 125 25
VS (nl) 262 20
fP,e (%) 0.113 26
fG,e (%) 0.0900 24
fS,e (%) 3.74 71
Stochastic parameters homogenate
Variance of paracetamol proportional residual error (2) 0.191 17
Variance of paracetamol-glucuronide proportional residual error (2) 0.279 17
Variance of paracetamol-sulfate proportional residual error (2) 0.0521 29
Correlation of paracetamol and paracetamol-glucuronide proportional residual error (2) 20.220 13a
Correlation of paracetamol-glucuronide and paracetamol-sulfate proportional residual error (2) 20.0358 15a
Variance of paracetamol additive residual error (pmol/larva) 0.00461 93
Variance of paracetamol-glucuronide additive residual error (pmol/larva) 0.0131 71
Stochastic parameters blood
Variance of paracetamol additive residual error (pmol/nl) 0.0148 70
Variance of paracetamol-glucuronide proportional residual error (2) 0.393 50
Variance of paracetamol-sulfate proportional residual error (2) 0.994 33
Stochastic parameters excreted compound
Variance of paracetamol additive residual error (pmol/larva) 0.000207 41
Variance of paracetamol-glucuronide proportional residual error (2) 0.678 23
Variance of paracetamol-sulfate proportional residual error (2) 0.941 47
Variance of paracetamol-sulfate additive residual error (pmol/larva) 0.00113 110
fG,e, recovery fraction excreted paracetamol-glucuronide; fP,e, recovery fraction excreted paracetamol; fS,e, recovery fraction excreted paracetamol-sulfate; ka, absorption rate
constant; kG,e, paracetamol-glucuronide excretion rate; kP,e, paracetamol excretion rate; kPG,f, metabolic formation rate for glucuronidation; kPS,f,0, metabolic formation rate for
sulfation at time point 0; kS,e, paracetamol-sulfate excretion rate; VG, paracetamol-glucuronide distribution volume; VP, paracetamol distribution volume; VS, paracetamol-
sulfate distribution volume; t50, time at which time-dependent metabolic formation rate for sulfation is at 50%.
aRSE of the estimate for covariance.











the experiment with germ-free larvae that lack microbiota
(data not shown). To establish whether paracetamol-glucuronide
andparacetamol-sulfatewere themajormetabolites in zebrafish,
other metabolites were identified and measured by LC-
MS. Two minor metabolites, 3-methoxy-paracetamol and
n-acetylcysteine-paracetamol, were detected around or below
the limit of quantification, resulting in a negligible impact on
the mass balance.
Low fractions of paracetamol and its metabolites excreted
according to the model were recovered in the washout
experiment, for which an empirical recovery fraction was
estimated. This might be due to adhesion of these compounds
Fig. 5. Relationship between paracetamol clearance and bodyweight of 13 vertebrate species. Clearance in zebrafish larvae at 5 days post fertilization is
depicted as the clearance value at t5 0 (closed square) and t5 ‘ (open square), with the vertical line depicting the range in clearance over time. Mature
individuals are shown in blue, immature individuals in red. The correlation (dashed line; shaded area, 95% confidence interval) is based on values from
mature individuals of the higher vertebrates only. Adapted with permission from Kantae et al. (2016).
Fig. 6. Relationship between distribution volume of paracetamol and bodyweight of 14 vertebrate species, including zebrafish larvae at 5 days post
fertilization. Mature individuals are shown in blue, immature individuals in red. The correlation (dashed line; shaded area, 95% confidence interval) is
based on values from mature individuals in higher vertebrates only. Raw data can be found in Supplemental Table 2.











to the wells. Moreover, the accuracy of the measurements of
the excreted amounts may be negatively impacted by meas-
urements being close to the limit of quantification. A sensi-
tivity analysis excluding these measurements showed similar
parameter estimates, suggesting negligible impact of these
data on the final model outcome.
Limitations in estimating distribution volume and thereby
absolute clearance values are overcome by having measure-
ments of both drug concentrations in the blood as well as total
amounts in the larvae. However, it is not clear whether this
approach will also be applicable to studying the pharmacoki-
netics of lipophilic drugs, as these drugs may be more difficult
to wash off the larvae due to skin adhesion, which complicates
measurements of total internal amounts. However, alterna-
tivemethods for oral dosing using nanoparticlesmight provide
a solution for this limitation.
In conclusion, an improved understanding of pharmacoki-
netics in the vertebrate model organism zebrafish larva is
presented. Based on the method developed to sample blood
from these larvae, absolute clearance resulting from different
metabolic routes, as well as distribution could be quantified
for the paradigm compound paracetamol. A comparison of the
estimated absolute clearance and distribution volume with
those reported for higher vertebrates shows a good correlation.
This improved confidence in the translational value of the
zebrafish can contribute to the role of this small vertebrate in
drug discovery and development.
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